Kiniksa CEO awarded 120K-share option, RSUs
CEO Sanj K. Patel received new RSU and option grants and exercised prior RSUs into shares largely held through family trusts.
Rhea-AI Filing Summary
Kiniksa Pharmaceuticals International, plc (KNSA) reported multiple equity compensation and related transactions for Chairman & CEO Sanj K. Patel on September 1, 2026. He received 30,050 Restricted Share Units and a share option for 120,150 Class A Ordinary Shares at $79.28 per share, both vesting over time. On the same date, previously granted RSUs covering 31,318 shares were exercised into Class A Ordinary Shares, which were acquired indirectly by The Patel Family Irrevocable Trust of 2025, and 15,144 shares were delivered or withheld at $79.28 per share to pay the exercise price or tax liability. Following these and prior transactions, indirect holdings include 109,795 shares in The Marina 2016 Irrevocable Trust and 51,794 shares in The Anglia 2013 Revocable Trust.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Share Unit F1, F2 | 30,050 | $0.00 | $0.00 |
| Grant/Award | Share Option F3 | 120,150 | $0.00 | $0.00 |
| Exercise | Restricted Share Unit F1, F4 | 8,609 | $0.00 | $0.00 |
| Exercise | Restricted Share Unit F1, F5 | 6,237 | $0.00 | $0.00 |
| Exercise | Restricted Share Unit F1, F6 | 6,481 | $0.00 | $0.00 |
| Exercise | Restricted Share Unit F1, F7 | 9,991 | $0.00 | $0.00 |
| Exercise | Class A Ordinary Share F1 | 9,991 | -- | -- |
| Exercise | Class A Ordinary Share F1 | 6,481 | -- | -- |
| Exercise | Class A Ordinary Share F1 | 6,237 | -- | -- |
| Exercise | Class A Ordinary Share F1 | 8,609 | -- | -- |
| Exercise Price or Tax Liability | Class A Ordinary Share | 15,144 | $79.28 | $1.20M |
| holding | Class A Ordinary Share | -- | -- | -- |
| holding | Class A Ordinary Share | -- | -- | -- |
Footnotes (7)
- F1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
- F2. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026.
- F3. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
- F4. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
- F5. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.
- F6. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
- F7. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Key Figures
Key Terms
exercise price financial
vesting commencement date financial
Irrevocable Trust financial
FAQ
What new equity awards did KNSA grant to CEO Sanj K. Patel on September 1, 2026?
Is there a Rule 10b5-1 trading plan associated with this KNSA Form 4?
How do the new KNSA RSU grants to Sanj K. Patel vest over time?
AI-generated analysis. How Rhea-AI works. Not financial advice.